
SCARD Pool report for 01-01-2005 to 31-12-2005

Participants	Doctors	12	
	Patients	216	
Specimens	New lesions	355	82.75%
	Previously biopsied lesions	74	17.25%
	Total lesions	429	100.00%

Breakdown of new versus previously biopsied specimens



Percentage of new lesions tested which were malignant	57.47%
Percentage of Definitively excised lesions that were malignant	61.03%
Lesions tested to find one melanoma (NNT)	6.20
Percentage of lesions tested for NMSC which were NMSC	69.60%
Ratio of New BCCs : New Melanomas	12:1

Accuracy

Diagnostic sensitivity

Melanomas	90.00% of 10
All NMSC	98.42% of 190
BCCs	97.52% of 121
SCCs	73.53% of 68

Positive predictive value

Melanomas	75.00% of 12
All NMSC	88.21% of 212
BCCs	55.66% of 212
SCCs	78.13% of 64

Adequacy

Percentage of definitively managed malignant cases where surgical margins were adequate

BCC	92.73% of 55
IEC/Bowens disease	100.00% of 11
SCC	82.76% of 29
Keratoacanthoma	100.00% of 1
Melanoma - in situ	100.00% of 5
Melanoma - invasive	0% of 0
Melanoma - invasive > 1mm	100.00% of 1
Other malignant	0% of 0

© 2026 SCARD Systems Pty Ltd

Lesion Breakdown

Histological Diagnosis

BCC (unspecified type)	30	8.43%
BCC - Superficial	29	8.15%
BCC - Nodular/Solid	51	14.33%
BCC - Aggressive	11	3.09%
IEC/Bowens disease	25	7.02%
SCC	42	11.80%
Keratoacanthoma	1	0.28%
Pinkus Fibroepithelioma	0	0%
Merkel cell tumour	0	0%
Other malignant	1	0.28%
NMSC Metastasis	0	0%
Melanoma - in situ	6	1.69%
Melanoma - invasive	2	0.56%
Melanoma - invasive > 1mm	2	0.56%
Melanoma - metastasis	0	0%
MELTUMP	0	0%
Naevus - other	13	3.65%
Naevus - dysplastic/Clark	21	5.90%
Naevus - blue	2	0.56%
Naevus - Spitz/Reed	0	0%
Naevus - Compound	0	0%
Solar keratosis	24	6.74%
Solar lentigo	1	0.28%
Seborrhoeic keratosis	42	11.80%
Lentigo Simplex	0	0%
Lichenoid keratosis (LPLK)	0	0%
Dermatofibroma	3	0.84%
Sebaceous gland hyperplasia	1	0.28%
Benign cyst	11	3.09%
Other benign	30	8.43%
Histology Pending	1	0.28%

Procedures

Definitive Surgical Management used to exclude melanoma

Ellipse	37	94.87%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	1	2.56%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%

© 2026 SCARD Systems Pty Ltd

	Specialist referral	1	2.56%
	Other	0	0%
Biopsy used to exclude melanoma			
	Punch - sample	6	25.00%
	Shave - sample	5	20.83%
	Incisional	0	0%
	Punch - removal	1	4.17%
	Shave - removal	0	0%
	Excisional	12	50.00%
	Curettage	0	0%
	Other	0	0%
Breakdown of definitive management procedures for malignant conditions			
	Ellipse	109	56.77%
	Flap	3	1.56%
	Graft - SSG	0	0%
	Graft - FTSG	0	0%
	No Closure	0	0%
	Shave/Saucerisation	1	0.52%
	Curettage & Cautery	19	9.90%
	Liquid N2 freeze/thaw	0	0%
	PDT	1	0.52%
	Imiquimod	17	8.85%
	5 FU cream	1	0.52%
	GP referral	0	0%
	Specialist referral	41	21.35%
	Other	0	0%
Breakdown of definitive management procedures for benign conditions			
	Ellipse	42	67.74%
	Flap	0	0%
	Graft - SSG	0	0%
	Graft - FTSG	0	0%
	No Closure	0	0%
	Shave/Saucerisation	0	0%
	Liquid N2 freeze/thaw	1	1.61%
	5 FU cream	2	3.23%
	GP referral	0	0%
	Specialist referral	1	1.61%
	Other	0	0%

Procedures (continued)

Percentage of procedures/closures that were complex

Complex Closures	0% of 73
Complex Closures (inc Curettage & Cautery)	0% of 87


Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

Nose	0	0% of 24
Lip	0	0% of 1
Ear	0	0% of 16
Eyelid	0	0% of 4
Other face	1	1.75% of 57
Scalp	1	9.09% of 11

© 2026 SCARD Systems Pty Ltd

Neck	0	0% of 11
Shoulder	1	5.88% of 17
Chest	0	0% of 22
Abdomen	1	33.33% of 3
Genitalia	0	0% of 3
Back	2	3.64% of 55
Buttock	0	0% of 0
Arm	2	11.76% of 17
Forearm	1	4.00% of 25
Hand Dorsal	0	0% of 20
Hand Palmar	0	0% of 0
Finger Dorsal	0	0% of 3
Finger Nail	0	0% of 0
Finger Palmar	0	0% of 0
Thigh	0	0% of 5
Leg	1	1.96% of 51
Foot Dorsal	0	0% of 2
Foot Plantar	0	0% of 4
Toe Dorsal	0	0% of 0
Toe Nail	0	0% of 0
Toe Plantar	0	0% of 0
Palm Or Sole	0	0% of 0



© 2026 SCARD Systems Pty Ltd